Definition

A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against discoid domain receptor type 1 (DDR1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DDR1 monoclonal antibody PRTH-101 specifically targets, binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells in the tumor microenvironment (TME) from interacting with and attacking the tumor. By blocking DDR1, PRTH-101 causes the collagen fibers lose alignment and loosen. This creates gaps in the tumor barrier, thereby allowing cytotoxic T-cells to enter and attack the tumor.